Synapse - Michael Morris

Results (584)

Meta-analysis evaluating the impact of site of metastasis on overall survival in men with castration-resistant prostate cancer

Journal Article

Halabi, S.; Kelly, W. K.; Ma, H.; Zhou, H.; Solomon, N. C.; Fizazi, K.; Tangen, C. M.; Rosenthal, M.; Petrylak, D. P.; Hussain, M.; more...
Journal of Clinical Oncology (2016)

Fulltext@MSK | Save

Synthesis and in vivo imaging of 16β-[18F]fluoro-5α-dihydrotestosterone in castration resistant prostate cancer

Meeting Abstract

Tochon-Danguy, H.; Ackermann, U.; Poniger, S.; Chan, G.; Morris, M.; Lewis, J.; Lyashchenko, S.; Scott, A.
Internal Medicine Journal (2016)

Fulltext@MSK | Save

Trial design and objectives for castration-resistant prostate cancer: Updated recommendations from the prostate cancer clinical trials working group 3

Journal Article

Scher, H. I.; Morris, M. J.; Stadler, W. M.; Higano, C.; Basch, E.; Fizazi, K.; Antonarakis, E. S.; Beer, T. M.; Carducci, M. A.; Chi, K. N.; more...
Journal of Clinical Oncology (2016)

Fulltext@MSK | Save

Automated Bone Scan Index as a quantitative imaging biomarker in metastatic castration-resistant prostate cancer patients being treated with enzalutamide

Journal Article

Anand, A.; Morris, M. J.; Larson, S. M.; Minarik, D.; Josefsson, A.; Helgstrand, J. T.; Oturai, P. S.; Edenbrandt, L.; Røder, M. A.; Bjartell, A.
EJNMMI Research (2016)

Fulltext@MSK | Save

Analytic validation of the automated bone scan index as an imaging biomarker to standardize quantitative changes in bone scans of patients with metastatic prostate cancer

Journal Article

Anand, A.; Morris, M. J.; Kaboteh, R.; Bath, L.; Sadik, M.; Gjertsson, P.; Lomsky, M.; Edenbrandt, L.; Minarik, D.; Bjartell, A.
Journal of Nuclear Medicine (2016)

Fulltext@MSK | Save

A molecular model for predicting overall survival in patients with metastatic clear cell renal carcinoma: Results from CALGB 90206 (Alliance)

Journal Article

Kim, H. L.; Halabi, S.; Li, P.; Mayhew, G.; Simko, J.; Nixon, A. B.; Small, E. J.; Rini, B.; Morris, M. J.; Taplin, M. E.; more...
EBioMedicine (2015)

Fulltext@MSK | Save

A phase I/II study for analytic validation of 89Zr-J591 immunoPET as a molecular imaging agent for metastatic prostate cancer

Journal Article

Pandit-Taskar, N.; O'Donoghue, J. A.; Durack, J. C.; Lyashchenko, S. K.; Cheal, S. M.; Beylergil, V.; Lefkowitz, R. A.; Carrasquillo, J. A.; Martinez, D. F.; Fung, A. M.; more...
Clinical Cancer Research (2015)

Fulltext@MSK | Save

Baseline characteristics, number of radium-223 (Ra-223) injections, and overall survival (OS) in US Expanded Access Program (EAP) and ALSYMPCA

Meeting Abstract

Sartor, O.; Coleman, R. E.; Morris, M. J.; Nilsson, S.; Shore, N.; Sweeney, C.; Vogelzang, N. J.; Petrenciuc, O.; Gratt, J.; Parker, C.
European Journal of Cancer (2015)

Fulltext@MSK | Save

Reply to K. Lu

Journal Article

Morris, M. J.
Journal of Clinical Oncology (2015)

Fulltext@MSK | Save

Everolimus combined with gefitinib in patients with metastatic castration-resistant prostate cancer: Phase 1/2 results and signaling pathway implications

Journal Article

Rathkopf, D. E.; Larson, S. M.; Anand, A.; Morris, M. J.; Slovin, S. F.; Shaffer, D. R.; Heller, G.; Carver, B.; Rosen, N.; Scher, H. I.
Cancer (2015)

Fulltext@MSK | Save